Literature DB >> 34883213

Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?

Binxin Cui1, Lin Lin1, Bangmao Wang2, Wentian Liu2, Chao Sun3.   

Abstract

Saccharomyces boulardii (S. boulardii) is a probiotic yeast that has been elucidated to be efficacious in fighting various gastrointestinal diseases in preclinical as well as clinical studies. Its general mechanisms of probiotic action in the treatment of gastrointestinal conditions cover multifaceted aspects, including immune regulation, production of antimicrobial substances, pathogen competitive elimination, gut barrier integrity maintenance, intestinal trophic effect and antioxidant potency. In this review, basic knowledge with regard to the gut-liver axis, available probiotics remedies and mechanistic insights of S. boulardii as probiotics will be elucidated. In addition, we summarize the therapeutic potential of S. boulardii in several liver diseases evident from both bench and bedside information, such as acute liver injury/failure, fibrosis, hepatic damages due to metabolic disturbance or infection and obstructive jaundice. Future prospects in relation to medicinal effects of S. boulardii are also exploited and discussed on the basis of novel and attractive therapeutic concept in the latest scientific literature.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antioxidant; Liver disease; Liver injury; Probiotics; Saccharomyces boulardii; Saccharomyces cerevisiae

Mesh:

Year:  2021        PMID: 34883213     DOI: 10.1016/j.phrs.2021.106022

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  2 in total

1.  Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial.

Authors:  Roman Maslennikov; Irina Efremova; Vladimir Ivashkin; Maria Zharkova; Elena Poluektova; Elena Shirokova; Konstantin Ivashkin
Journal:  World J Hepatol       Date:  2022-08-27

2.  Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.

Authors:  Jungyeon Kim; Yu Eun Cheong; Sora Yu; Yong-Su Jin; Kyoung Heon Kim
Journal:  Microb Cell Fact       Date:  2022-10-07       Impact factor: 6.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.